Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Trial design of AGO trial, intense dose-dense epirubicin, paclitaxel,... | Download Scientific Diagram
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
Real world experience with dose dense ac-paclitaxel: Two canadian cancer centers' experience | Semantic Scholar
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial | Journal of Clinical Oncology
ESMO 2022: Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
ESMO 2022: Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Current status of dose-dense chemotherapy for breast cancer | SpringerLink
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | British Journal of Cancer
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. | Semantic Scholar
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor - ScienceDirect
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - ScienceDirect
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
